IMMU Immunicum AB

Immunicum bjuder in till investerarmöte med bolagets VD

Immunicum bjuder in till investerarmöte med bolagets VD

Pressmeddelande 

28 October 2021

Immunicum bjuder in till investerarmöte med bolagets VD

Immunicum AB (publ; IMMU.ST) tillkännagav idag att bolaget måndagen den 15 november bjuder in till ett möte där bolagets investerare för första gången får träffa Immunicums vd, Erik Manting och andra medlemmar ur ledningsgruppen. De kommer att svara på frågor om bolagets vision, kliniska studier och hur man arbetar med att addressera viktiga utmaningar inom området för cancerterapi.

Mötet är tänkt att vara av informell karaktär och deltagarna välkomnas att ställa frågor. Antalet deltagarplatser är begränsat, därför gäller först-till-kvarn-principen.

“Vi är dedikerade vår strategi liksom att hålla kontakten med våra investerare. Efter en lång period av Covid 19-relaterade restriktioner ser jag fram emot att personligen få träffa nuvarande aktieägare, investerare och andra intressenter för första gången sedan jag blev Immunicums vd”, säger Erik Manting, CEO på Immunicum.

Evenemanget kommer att hållas på engelska men alla som vill ställa frågor på svenska är välkomna att göra det. Efter samtalet ges tillfälle till mingel där det serveras ett lättare tilltugg och något att dricka.

Datum: måndagen den 15 november

Plast: Västra Trädgårdsgatan 15, Stockholm (Tändstickspalatset)

Tid: 18.00 - 19.00, registrering från 17.30

Vänligen anmäl ditt intresse att deltaga genom att skicka mail till innan den 10 november.



FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA:

Erik Manting

Chief Executive Officer

E-mail:  

INVESTOR RELATIONS

Kristina Windrup Olander

Spikinc AB

Telephone:

E-mail:  

About Immunicum AB (publ)

Immunicum is a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm.

Bilaga



EN
28/10/2021

Underlying

IMMUImmunicum AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immunicum AB

Free Trial
IMMU IMMUNICUM AB

Mendus AB: 2 directors

Two Directors at Mendus AB bought 29,328 shares at 6.777SEK. The significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

10/24/25 October 24, 2025 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Collaboration unveils path forward for ilixadencel

Mendus has announced a collaboration with Institut Bergonié, an established comprehensive cancer centre in France, to test ilixadencel in soft tissue sarcomas (STS) as part of an ongoing Phase I/II basket trial (REGOMUNE). The trial is a multi-centre, prospective open-label study assessing the combination of regorafenib (a tyrosine kinase inhibitor) and avelumab (an immune checkpoint inhibitor) in various solid tumours. Ilixadencel will be evaluated along with a combination in one of the treatme...

07/24/24 July 24, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Recent clinical data highlight vididencel’s potential

Mendus recently presented positive data from two ongoing clinical studies, ADVANCE II and ALISON, at the EHA and ESMO conferences, respectively. While the Phase I ALISON trial, evaluating lead asset vididencel in ovarian cancer, met its primary endpoint of generating sufficient vaccine-induced responses (VIR), further analysis of ADVANCE II data (studying vididencel as a maintenance therapy in AML) confirmed the drug’s potential in generating a broader immune response through both T-cell and B-c...

06/21/24 June 21, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - All hands on deck as inflection points approach

With Mendus’s Q124 results, management recapped its clinical priorities, which are all progressing as expected. The focus remains on the AMLM22-CADENCE trial for lead cancer vaccine vididencel, in combination with oral azacitidine as a maintenance treatment for acute myeloid leukaemia (AML). R&D expenses came in slightly ahead of expectations with the ramp up in clinical activity, including preparation for the subsequent pivotal Phase III trial, with large-scale manufacturing of vididencel (plan...

05/20/24 May 20, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Gross proceeds of c SEK69m to advance pipeline

Mendus has reported gross proceeds of c SEK69.1m from the exercise of series TO3 warrants that were issued in connection with the July 2023 raise of SEK317m. Management anticipates that these proceeds will extend the cash runway to Q325 and will be applied to progress its clinical pipeline, mainly in preparation for a registrational trial for lead cancer vaccine vididencel, targeting acute myeloid leukaemia (AML) in the maintenance setting. Management expects the registrational study to commence...

04/04/24 April 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch